One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Aeterna Zentaris logo
Aeterna Zentaris AEZS
report update icon

Quarterly report 2025-Q4
added 05-08-2026

Aeterna Zentaris Income Statement 2025-2011 | AEZS

Brief overview of financial results at Aeterna Zentaris

This overview is based on financial performance over the past five years. The revenue attributed to Aeterna Zentaris moved from $3.7 million to $7.5 million between the two endpoints. The total change was +105.3%, with a CAGR of approximately 15.5%. The trajectory reflects meaningful expansion of the business.

Gross profit was 1.3 million dollars at the start and 2.6 million dollars at the end of the period (+98.3%). The relationship between revenue and direct costs remained stable. The gross margin was 36.6% at the start and 35.3% at the end. The economics of the core business remained steady.

The five-year EBITDA result moved by −87.2%: from −5.7 million dollars to −10.7 million dollars. The operating result developed less favorably than sales. EBITDA margin moved from −156.2% to −142.5%. A wider margin confirms stronger operating efficiency.

Net income moved from −5.1 million dollars at the start to −10.4 million dollars at the end. The period ended with a larger loss than it began with.

Summary assessment

The current trajectory does not yet confirm a sustainable recovery. The constructive conclusion rests on an improving EBITDA margin and sales growth. Caution is warranted because of a narrow EBITDA buffer, a weaker final result and weaker gross profitability. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Aeterna Zentaris

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 14.8 M 3.66 M 5.02 M 41.4 M 28.3 M 18.7 M 63 M 32.3 M 26.9 M 3.99 B 31.3 M 38.6 M 59.9 M 158 M

Shares

3.17 M 2.58 M 1.85 M 1.84 M 115 M 41.1 M 17.5 M 16.4 M 15 M 10.3 M 65.4 M 590 K 295 K 198 K 158 K

Historical Prices

- 5.72 1.98 2.73 0.36 0.69 1.07 3.83 2.16 3.15 3.25 53 127 286 1.03 K

Net Income

-10.4 M -15.3 M -3.48 M 3.45 M -8.37 M -5.12 M -6.04 M 4.19 M -16.8 M -25 M 4.15 M -16.6 M 6.82 M -20.4 M -27.1 M

Revenue

7.5 M 9.59 M 7.14 M 14.6 M 5.26 M 3.65 M 532 K 26.9 M 923 K 911 K 11 K 11 K 6.18 M 33.7 M 36.1 M

Cost of Revenue

4.85 M 4.86 M 4.2 M 6.02 M 90 K 2.32 M 410 K 2.1 M - - - - - - -

Gross Profit

2.65 M 4.73 M 2.94 M 8.56 M - - - - - - 11 K 11 K 6.12 M 6.84 M 8.49 M

Operating Income

-10.7 M -18.3 M -4.63 M 4.32 M -8.67 M -5.71 M -10.2 M 9.84 M -23.1 M -29.5 M -34.9 M - - - -

EBITDA

-10.7 M -18.3 M -4.63 M 4.32 M -8.67 M -5.71 M -10.2 M 9.9 M -23 M -29.2 M -10.1 M -36.5 M -26.5 M -25.7 M -29.3 M

Operating Expenses

13.3 M 23 M 7.57 M 4.24 M 13.9 M 9.36 M 10.8 M 17 M 24 M 30.4 M 11 M 37.4 M 33.6 M 33.8 M 40.7 M

General and Administrative Expenses

10.1 M 10.4 M 5.5 M 2.84 M 5.92 M 4.76 M 6.62 M 8.89 M 8.2 M 7.15 M 4.68 M - - - -

All numbers in USD currency

Quarterly Income Statement Aeterna Zentaris

2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

3.17 M 3.18 M 3.17 M 3.14 M 2.58 M 3.11 M 2.22 M 1.21 M 1.85 M 4.86 M 4.86 M 4.86 M - - - 121 M - 121 M 121 M 95.4 M - 56.2 M 23.5 M 21.9 M - 16.9 M 17.3 M 16.4 M - 16.4 M 16.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-10.4 M -1.82 M -2.7 M -3.66 M -15.3 M -5.76 M -1.42 M -5.75 M -3.48 M -4.14 M -2.52 M -4.26 M - - - -2.64 M - -1.7 M -2.04 M -1.46 M - -1.14 M -3.45 M 779 K - -331 K 206 K -4.91 M - -2.51 M -2.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

7.5 M 1.48 M 2.75 M 1.5 M 9.59 M 1.87 M 2.34 M 4 K 7.14 M 3 K 2.25 M 2.13 M - - - 1.52 M - 602 K 599 K 1.67 M - 128 K 68 K 1.09 M - 283 K 194 K 37 K - 663 K 168 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

4.85 M 862 K 1.78 M 1.06 M 4.86 M 914 K 1.52 M 16 K 4.2 M 11 K 139 K 17 K - - - 79 K - 31 K 12 K 29 K - 33 K 12 K 862 K - - 101 K - - 494 K 197 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

2.65 M 621 K 974 K 443 K 4.73 M 957 K 819 K - 2.94 M - - - - - - - - - - - - - - - - 283 K 93 K - - 169 K -29 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-10.7 M -2.32 M -2.35 M -3.62 M -18.3 M -6.29 M -3.76 M -6.11 M -4.63 M -4.55 M -2.86 M -4.21 M - - - -2.81 M - -1.82 M -2.11 M -1.33 M - -1.74 M -1.44 M -1.28 M - -1.81 M -3.73 M -2.94 M - -3.01 M -3.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-10.7 M -2.32 M -2.35 M -3.62 M -18.3 M -6.29 M -3.76 M -6.11 M -4.63 M -4.55 M -2.86 M -4.21 M - - - -2.81 M - -1.82 M -2.11 M -1.33 M - -1.74 M -1.44 M -1.28 M - -1.81 M -3.73 M -2.94 M - -3.01 M -3.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

13.3 M 2.94 M 3.33 M - 23 M - - 6.11 M 7.57 M 4.55 M 5.1 M 6.34 M - - - 4.33 M - 2.42 M 2.71 M 3 M - 1.87 M 1.51 M 2.37 M - 2.09 M 3.93 M 2.98 M - 3.18 M 3.48 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

10.1 M 1.65 M 1.65 M 1.65 M 10.4 M 1.47 M 1.21 M 3.51 M 5.5 M 1.79 M 2.03 M 2.31 M - - - 1.56 M - 1.23 M 1.64 M 1.26 M - 1.18 M 1.14 M 1.12 M - 1.36 M 1.92 M 1.64 M - 2.44 M 2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Aeterna Zentaris (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 972.42 1.05 % $ 59.6 B niderlandNiderland
XBiotech XBiotech
XBIT
$ 1.97 3.2 % $ 60.1 M usaUSA
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.76 -2.09 % $ 2.99 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 30.86 2.22 % $ 3.14 B usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 41.4 2.35 % $ 3.28 B canadaCanada
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Zymeworks Zymeworks
ZYME
$ 31.45 2.08 % $ 1.62 B canadaCanada
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.15 -35.42 % $ 2.11 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 12.67 -0.98 % $ 3.02 B usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.66 -1.35 % $ 802 M britainBritain
Daré Bioscience Daré Bioscience
DARE
$ 0.69 1.75 % $ 7.71 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 1.78 -8.51 % $ 211 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 16.05 -2.85 % $ 217 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 103.0 0.08 % $ 12.3 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
$ 15.34 0.1 % $ 13.2 B chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
iBio iBio
IBIO
$ 0.78 -1.89 % $ 81.2 M usaUSA
Kodiak Sciences Kodiak Sciences
KOD
$ 108.01 0.85 % $ 5.75 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 0.02 -54.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 25.32 -3.78 % $ 1.22 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.91 1.9 % $ 1.24 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
- - $ 5.18 B usaUSA